Search

Search Results

• 

  PO22 | LONG-TERM ANTICOAGULANT THERAPY AND REDUCTION OF OVARIAN CANCER RECURRENCE: CLINICAL EVIDENCE OF A POTENTIAL ANTITUMOUR EFFECT J. Khizroeva¹, V. Bitsadze¹, A. Vorobev¹, A. Solopova¹, M. Tretyakova¹, N. Gashimova¹, K. Grigoreva¹, A. Khisamieva¹, J. Gris^1|2, I. Elalamy^1|3|4, G. Gerotziafas^1|3|4, A. Makatsariya¹ | ¹Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University, Moscow, Russia; ²Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; ³Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; ⁴Hospital Tenon, Paris, France

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.517

  118

  PDF: 28
• 

  PO21 | PSYCHOLOGICAL IMPACT OF CANCER-ASSOCIATED THROMBOSIS: DUAL BURDEN AND IMPLICATIONS FOR QUALITY OF LIFE AND INTEGRATED PATIENT-CENTERED CARE G. Gerotziafas^1|4, Y. Mitrou⁵, M. Marchetti⁶, P. Las Casa¹, A. Tafur⁷, V. Bitsadze³, J. Khizroeva³, D. Taizhanova⁸, D. Antic⁹, C. Frére¹⁰, A. Makatsariya³, L. Garderet^1|11, A. Escargueil¹, C. Ay¹², N. Lomatkin¹³, Z. Tazi-Mezalek¹⁴, M. Sassi¹⁵, M. Catalano^4|16, J. Gligorov^1|17, J. Caprini¹⁸, P. Van Dreden^1|19, J. Fareed², A. Falanga⁶ | ¹Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP)Paris France; ²Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; ³Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; ⁴VAS-European Independent Foundation in Angiology/Vascular Medicine Milan Italy; ⁵Department of Phylosophy, National and Kapodistrian University of Athens, Greece; ⁶Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy. School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; ⁷Vascular Medicine, Endeavor Health, Evanston, IL, USA; Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA; ⁸Department of Internal Diseases, Karaganda Medical University Non-Commercial Joint Stock Company, Karaganda, Kazakhstan; ⁹Clinic for Hematology, University Clinical Center of Serbia, Faculty of Medicine University of Belgrade Belgrade Serbia; ¹⁰Department of Hematology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, INSERM UMRS-1166 Institute of Cardiometabolism and Nutrition, Paris, France; ¹¹Clinical Haematology Department, Sorbonne Université, Pitié-Salpêtrière Hospital, APHP, Paris; ¹²Department of Internal Medicine I, Clinical Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria; ¹³Cardiology Division, Central Clinical Hospital of Presidential Administration, Moscow, Russia; ¹⁴Department of Internal Medicine, Hématologie Clinique, Centre Hospitalo-Universitaire Ibn Sina, Université Mohammed V de Rabat, Rabat, Morocco; ¹⁵Hematology Laboratory of Maternity and Neonatal Center of Monastir, Faculty of Pharmacy of Monastir, Monastir, Tunisia; ¹⁶Inter-University Research Center on Vascular Diseases, University of Milan-L Sacco Hospital, Milan, Italy; ¹⁷Medical Oncology Department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France; ¹⁸Vascular Surgery, Pritzker School of Medicine at the University of Chicago, Chicago, USA; ¹⁹Clinical Research, Diagnostica Stago, Gennevilliers, France

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.516

  114

  PDF: 32
• 

  PO20 | DYSFUNCTION OF THE ADAMTS-13/VON WILLEBRAND FACTOR AXIS, MEDIATED BY NETOSIS, AS A DRIVER OF PROTHROMBOTIC STATE AND UNFAVORABLE PROGNOSIS IN ONCOGYNECOLOGICAL PATIENTS V. Bitsadze¹, E. Beloborodova², J. Khizroeva¹, A. Solopova¹, M. Tretyakova¹, N. Gashimova¹, K. Grigoreva¹, A. Tatarintseva¹, J. Christophe Gris^1|3, I. Elalamy^1|4|5, G. Gerotziafas^1|4|5, A. Makatsariya¹ | ¹Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; ²Clinic MEDSI Network of Medical Centers in Moscow, Russia; ³Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; ⁴Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; ⁵Hospital Tenon, Paris, France

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.515

  116

  PDF: 30
• 

  PO19 | THE INTER-RELATIONSHIP BETWEEN NETOSIS, THE ADAMTS-13/VWF AXIS, AND HEMOSTATIC ACTIVATION IN PATIENTS WITH GYNECOLOGICAL MALIGNANCIES: PROGNOSTIC SIGNIFICANCE AND IMPACT OF CHEMOTHERAPY A. Makatsariya¹, E. Beloborodova²,V. Bitsadze¹, J. Khizroeva¹, A. Vorobev¹, A. Solopova¹, M. Tretyakova¹, N. Gashimova¹, K. Grigoreva¹, A. Oskolkova¹, J. Christophe Gris^1|3, I. Elalamy^1|4|5, G. Gerotziafas^1|4|5 | ¹Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University Sechenov University, Moscow, Russia; ²MEDSI Network of Medical Centers, Moscow, Russia; ³Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; ⁴Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; ⁵Hospital Tenon, Paris, France

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.514

  101

  PDF: 36
• 

  PO30 | LONG-TERM ANTICOAGULANT THERAPY AND PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM IN ADVANCED OVARIAN CANCER V. Bitsadze ¹, A. Vorobev ¹, J. Khizroeva ¹, A. Solopova ¹, M. Tretyakova ¹, N. Gashimova ¹, K. Grigoreva ¹, A. Khisamieva ¹, J. Gris ^1|2, I. Elalamy^1|3|4, G. Gerotziafas^1|3|4, A. Makatsariya¹ | ¹Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; ²Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; ³Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; ⁴Hospital Tenon, Paris, France

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.525

  96

  PDF: 30